# Effectiveness of Exenatide Plus Dapagliflozin on 24 Hour Glucose Variability Measured by CGM. A Proof of Concept.

> **NCT03970044** · PHASE4 · COMPLETED · sponsor: **Consano Clinical Research, LLC** · enrollment: 67 (actual)

## Conditions studied

- Diabetes Mellitus, Type 2

## Interventions

- **DRUG:** Exenatide 2 MG
- **DRUG:** Dapagliflozin 10 MG

## Key facts

- **NCT ID:** NCT03970044
- **Lead sponsor:** Consano Clinical Research, LLC
- **Sponsor class:** OTHER
- **Phase:** PHASE4
- **Study type:** INTERVENTIONAL
- **Status:** COMPLETED
- **Start date:** 2019-07-02
- **Primary completion:** 2021-06-01
- **Final completion:** 2021-06-01
- **Target enrollment:** 67 (ACTUAL)
- **Last updated:** 2021-08-30


## Primary source

ClinicalTrials.gov registry: https://clinicaltrials.gov/study/NCT03970044

## Citation

> US National Library of Medicine, ClinicalTrials.gov registration NCT03970044, "Effectiveness of Exenatide Plus Dapagliflozin on 24 Hour Glucose Variability Measured by CGM. A Proof of Concept.". Retrieved via AI Analytics 2026-06-02 from https://api.ai-analytics.org/clinical/NCT03970044. Licensed CC0.

---

*[Clinical trials dataset](/datasets/clinical-trials) · CC0 1.0*